Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Rapid CommunicationShort Communication

The Effects of Rosuvastatin and the CYP51A1 Inhibitor LEK-935 on the Proteome of Primary Human Hepatocytes

Martin Wörner, Katja Melchior, Katalin Monostory, Jean-Marc Pascussi, Christian G. Huber and Rita Bernhardt
Drug Metabolism and Disposition March 2012, 40 (3) 414-418; DOI: https://doi.org/10.1124/dmd.111.040402
Martin Wörner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katja Melchior
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katalin Monostory
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Marc Pascussi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian G. Huber
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rita Bernhardt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Elevated amounts of cholesterol are thought to be involved in several severe diseases. Despite the fact that many studies have been performed and published, the action of cholesterol-lowering agents used to diminish the plasma cholesterol level is not fully understood yet. In this study, the effects of the HMG-CoA reductase inhibitor rosuvastatin and the new CYP51A1 inhibitor 2-((3,4-dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LEK-935) on the proteome of primary human hepatocytes were analyzed for the first time. To get an idea about interindividual differences, two different human donors were used. The cytosolic and microsomal fractions of the cells were analyzed in a semiquantitative manner by two-dimensional-polyacrylamide gel electrophoresis and capillary high-performance liquid chromatography-mass spectrometry, respectively. Thereby, a set of 44 proteins was found to be differentially presented. The chosen experimental set-up was validated by proteins already known to be affected by statins and involved in the cholesterol biosynthesis. Other proteins found to be regulated cannot be directly related to cholesterol metabolism and have not been described to be affected by cholesterol-lowering agents so far. Some of these proteins may represent interesting targets for further investigations into the analysis of severe side-effects as well as pleiotropic effects of the statins. During the proteome analysis of the two different donors, interindividual differences were observed that were validated by real-time reverse transcription-polymerase chain reaction measurements. Thus, new information and a deeper insight into the processes taking place inside cells treated with cholesterol-lowering agents can be drawn from this study.

Footnotes

  • This work was funded as a part of the STEROLTALK project within the 6th Framework Program of the European Commission [EC Contract LSHG-CT-2005-512096].

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

    http://dx.doi.org/10.1124/dmd.111.040402.

  • ↵Embedded Image The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.

  • ABBREVIATIONS:

    RSV
    rosuvastatin
    LEK-935
    2-((3,4-dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol
    2D-PAGE
    two-dimensional-polyacrylamide gel electrophoresis
    HPLC-MS
    high-performance liquid chromatography coupled to mass spectrometry
    RT-PCR
    reverse transcription-polymerase chain reaction.

  • Received September 2, 2011.
  • Accepted December 15, 2011.
  • Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 40 (3)
Drug Metabolism and Disposition
Vol. 40, Issue 3
1 Mar 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Effects of Rosuvastatin and the CYP51A1 Inhibitor LEK-935 on the Proteome of Primary Human Hepatocytes
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rapid CommunicationShort Communication

EFFECTS OF CHOLESTEROL-LOWERING DRUGS ON THE PROTEOME OF HEPATOCYTES

Martin Wörner, Katja Melchior, Katalin Monostory, Jean-Marc Pascussi, Christian G. Huber and Rita Bernhardt
Drug Metabolism and Disposition March 1, 2012, 40 (3) 414-418; DOI: https://doi.org/10.1124/dmd.111.040402

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Rapid CommunicationShort Communication

EFFECTS OF CHOLESTEROL-LOWERING DRUGS ON THE PROTEOME OF HEPATOCYTES

Martin Wörner, Katja Melchior, Katalin Monostory, Jean-Marc Pascussi, Christian G. Huber and Rita Bernhardt
Drug Metabolism and Disposition March 1, 2012, 40 (3) 414-418; DOI: https://doi.org/10.1124/dmd.111.040402
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results and Discussion
    • Authorship Contributions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Preincubation Effects on Inhibition of OCT1 by CsA
  • Carbamazepine Metabolite and Hypersensitivity Reactions
  • SULT4A1 Preserves Mitochondrial Function
Show more Short Communications

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics